Instrument Inactif

Autres langues LOCT WALK Nasdaq

Actions

LWACU

US54015L3015

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K	26/06
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	24/06
Top Midday Decliners	24/06
Sector Update: Health Care Stocks Advance Monday Afternoon	24/06
EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives	24/06
EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq	24/06
EFFECTOR Therapeutics, Inc Appoints Craig R. Jalbert as CEO	24/06
EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board	24/06
EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	20/05
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Health Care Down on Retreat From Risk -- Health Care Roundup	04/04
Top Midday Decliners	04/04
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04/04
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	04/04
Top Premarket Decliners	26/03
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	25/03
EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	05/02
EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	25/01
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	09/01
EFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024	09/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues LOCT WALK Nasdaq

Actions

LWACU

US54015L3015

Autres langues

Filtres